Communiqués Ocugen, Inc. Börse Stuttgart

Actions

2H51

US67577C1053

Recherche biotechnologique et médicale

Marché Fermé - Börse Stuttgart 21:56:40 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,9030 ^EUR	+1,35%		+1,12%	-29,18%

25/09	Ocugen obtient une autorisation provisoire pour l'OCU400 aux Bahamas	MT
25/09	Ocugen, Inc. reçoit une approbation provisoire et la désignation prioritaire au titre du Longevity and Regenerative Therapies Act aux Bahamas pour fournir OCU400 aux patients atteints de rétinite pigmentaire	CI

Communiqués

30/09	Ocugen to Participate in Upcoming Scientific Conferences	GL
29/09	Ocugen to Participate in Upcoming October Investor and Industry Conferences	GL
25/09	Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa	GL
01/09	Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	GL
25/08	Ocugen to Participate in Upcoming September Investor and Industry Conferences	GL
06/08	Ocugen: Q2 Earnings Snapshot	AQ
06/08	Ocugen Provides Business Update with Second Quarter 2026 Financial Results	GL
31/07	Ocugen to Participate in Upcoming August Investor Conferences	GL
30/07	Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration	AQ
29/07	Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration	GL
28/07	Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results	GL
13/07	Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa	GL
01/07	Ocugen to Participate in Upcoming July Industry Conferences	GL
02/06	Ocugen to Participate in Upcoming June Investor and Industry Conferences	GL
14/05	Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes	GL
13/05	Ocugen to Participate in Upcoming May Scientific and Investor Conferences	GL
05/05	Ocugen: Q1 Earnings Snapshot	AQ
05/05	Ocugen Provides Business Update with First Quarter 2026 Financial Results	GL
05/05	Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes	GL
04/05	Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes	GL
29/04	Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results	GL
23/04	Ocugen to Present at April 2026 Investor and Industry Conferences	GL
01/04	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease	GL
24/03	Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	GL
23/03	Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy	GL